These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 7763035)

  • 1. Correlation of proliferating cell nuclear antigen assessment, histologic parameters and age with survival in patients with glioblastoma multiforme.
    Karkavelas G; Mavropoulou S; Fountzilas G; Christoforidou V; Karavelis A; Foroglou G; Papadimitriou C
    Anticancer Res; 1995; 15(2):531-6. PubMed ID: 7763035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of tumor p53 and PCNA with response and survival of glioblastoma in patients treated with an ECOG protocol of pre-irradiation chemotherapy.
    Grunnet ML; O'Neill A; Gilbert M; Hellman R
    Clin Neuropathol; 2000; 19(5):230-4. PubMed ID: 11048748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic analysis of astrocytic gliomas correlating histological parameters with the proliferating cell nuclear antigen labelling index (PCNA-LI).
    Cruz-Sánchez FF; Ferreres JC; Figols J; Palacin A; Cardesa A; Rossi ML; Val-Bernal JF
    Histol Histopathol; 1997 Jan; 12(1):43-9. PubMed ID: 9046042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of three quantitation methods for PCNA immunostaining: applicability and relation to survival in 83 astrocytic neoplasms.
    Haapasalo HK; Sallinen PK; Helén PT; Rantala IS; Helin HJ; Isola JJ
    J Pathol; 1993 Nov; 171(3):207-14. PubMed ID: 7903983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.
    McKeever PE; Ross DA; Strawderman MS; Brunberg JA; Greenberg HS; Junck L
    J Neuropathol Exp Neurol; 1997 Jul; 56(7):798-805. PubMed ID: 9210876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of proliferative markers Ki-67 (MIB-1) and proliferating cell nuclear antigen (PC10) in transitional cell carcinoma of the renal pelvis.
    Cheville JC; Terrell RB; Cohen MB
    Mod Pathol; 1994 Sep; 7(7):794-800. PubMed ID: 7824516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Needle biopsy of hepatocellular carcinoma: assessment of prognostic contribution of histologic parameters including proliferating cell nuclear antigen labeling and correlations with clinical outcomes. Group d'Etude et de Traitement du Carcinoma Hépatocellulaire.
    Chapel F; Guettier C; Chastang C; Rached AA; Mathieu D; Tepper M; Beaugrand M; Trinchet JC
    Cancer; 1996 Mar; 77(5):864-71. PubMed ID: 8608476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCNA-LII, Ki-67 immunostaining, p53 activity and histopathological variables in predicting the clinical outcome in patients with parathyroid carcinoma.
    Lumachi F; Ermani M; Marino F; Iacobone M; Baldessin M; Cappuzzo G; Zanella S; Favia G
    Anticancer Res; 2006; 26(2A):1305-8. PubMed ID: 16619538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ampullary carcinoma: prognostic significance of ploidy, cell-cycle analysis and proliferating cell nuclear antigen (PCNA).
    Crucitti A; Masetti R; Breccia C; Coppola R; Magistrelli P; Nuzzo G; Maggiano N; Picciocchi A
    Hepatogastroenterology; 1999; 46(26):1187-91. PubMed ID: 10370689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67.
    Taftachi R; Ayhan A; Ekici S; Ergen A; Ozen H
    BJU Int; 2005 Mar; 95(4):650-4. PubMed ID: 15705097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of proliferating cell nuclear antigen (PCNA) and p 53 protein correlate with prognosis of patients with oral squamous cell carcinoma.
    Kurokawa H; Yamashita Y; Takeda S; Miura K; Murata T; Kajiyama M
    Fukuoka Igaku Zasshi; 1999 Jan; 90(1):6-13. PubMed ID: 10087668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
    Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic values of proliferating cell nuclear antigen (PCNA) and Ki-67 for radiotherapy of oesophageal squamous cell carcinomas.
    Okuno Y; Nishimura Y; Kashu I; Ono K; Hiraoka M
    Br J Cancer; 1999 May; 80(3-4):387-95. PubMed ID: 10408843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma].
    Reitmaier M; Rudlowski C; Biesterfeld S; Rath W; Schröder W
    Zentralbl Gynakol; 2000; 122(7):361-7. PubMed ID: 10951706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas.
    Maiuri F; Del Basso De Caro ML; Iaconetta G; Peca C; Esposito M; de Divitiis E
    Zentralbl Neurochir; 2006 Nov; 67(4):204-9. PubMed ID: 17106834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunohistochemical study of the expression of proliferating cell nuclear antigen in astrocytic gliomas of the cerebral hemispheres].
    Korshunov AG; Sycheva RV
    Arkh Patol; 1996; 58(2):32-7. PubMed ID: 8712938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The morphology of perinecrotic tumor cell nuclei in glioblastomas shows a significant relationship with survival time.
    Nafe R; Franz K; Schlote W; Schneider B
    Oncol Rep; 2006 Sep; 16(3):555-62. PubMed ID: 16865255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of relative proliferation rates of Wilms' tumor components using proliferating cell nuclear antigen and MIB-1 (Ki-67 equivalent antigen) immunostaining and assessment of mitotic index.
    Khine MM; Aung W; Sibbons PD; Howard CV; Clapham E; McGill F; Van Velzen D
    Lab Invest; 1994 Jan; 70(1):125-9. PubMed ID: 7905542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of p53 in glioblastoma multiforme cells: relationship to survival, proliferation and glycosylation.
    Ehrmann J; Kolár Z; Kala M; Vojtĕsek B; Komenda S
    Cesk Patol; 1995 Aug; 31(3):87-91. PubMed ID: 9444787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell proliferation in renal cell carcinoma. A clinical study with special reference to prognosis.
    Larsson P
    Scand J Urol Nephrol Suppl; 1994; 165():1-48. PubMed ID: 7871395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.